All Releases
 |
Myriad Genetics Announces Presentation of Lung Cancer Study at American Society for Clinical Oncology Annual Meeting
May 16, 2012
|
15.0 KB |
|
| |
SALT LAKE CITY, May 16, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today the presentation of a study at the American Society of Clinical Oncology® (ASCO) Annual Meeting, including the complete results from a study titled, "Use of a proliferation-based mRNA signature to predict outcome in early-stage non-small cell l...
|
|
Myriad RBM Announces the Launch of OncologyMAP® v. 2.0
May 9, 2012
|
16.3 KB |
|
| |
Salt Lake City, UT (PRWEB) May 09, 2012
Myriad Genetics (NASDAQ: MYGN) announced today that Myriad RBM, a wholly owned subsidiary of Myriad Genetics, has launched OncologyMAP® v. 2.0, a powerful research tool developed with funding and direction from the National Cancer Institute and the Cancer Prevention Research Institute of Texas. Oncolo...
|
|
Myriad Genetics Reports Record Third Fiscal Quarter 2012 Results
May 1, 2012
|
25.4 KB |
|
| |
SALT LAKE CITY, May 1, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its third fiscal quarter and nine months ending March 31, 2012. Revenue for the third fiscal quarter was $129.8 million, an increase of 27 percent over the $102.4 million reported in the third fiscal quarter of 2011. Earnings per diluted ...
|
|
Myriad Genetics to Announce Fiscal 2012 Third Quarter Results on Tuesday, May 1, 2012
Apr 10, 2012
|
12.2 KB |
|
| |
SALT LAKE CITY, April 10, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the third fiscal quarter following the close of market on Tuesday, May 1, 2012.
The Company will also host a conference call on Tuesday, May 1, 2012 at 4:30 P.M. Eastern to review the financial resu...
|
|
Myriad Study Finds High Prevalence of Mutations in the PMS2 Gene
Mar 29, 2012
|
15.3 KB |
|
| |
SALT LAKE CITY, March 29, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled, "Representation of PMS2 mutations in patients seeking genetic testing for Lynch syndrome," was presented at the 2012 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. The study...
|
|
Myriad and Cephalon Enter Into Companion Diagnostic Agreement
Mar 28, 2012
|
15.6 KB |
|
| |
SALT LAKE CITY, March 28, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has signed an agreement with Cephalon Inc., a subsidiary of Teva Pharmaceutical Industries Ltd Company, to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase I/II clinical study.
"We are extremely plea...
|
|
Supreme Court of the United States Remands Gene Patenting Case
Mar 26, 2012
|
17.5 KB |
|
| |
SALT LAKE CITY, March 26, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) reported today that the Supreme Court of the United States remanded the case of The Association for Molecular Pathology, et al., v. Myriad Genetics, Inc., et al (Docket No. 11-725) to the Federal Circuit Court of Appeals. As a result of this decision by the Supre...
|
|
Prolaris(R) Test Awarded Best Poster Honor at 27th Annual EAU Congress in Paris, France
Feb 27, 2012
|
16.2 KB |
|
| |
SALT LAKE CITY, Feb. 27, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled, "Validation of a panel of cell-cycle progression genes for improved risk-stratification in a contemporary radical prostatectomy cohort," won the best poster honor at the 27th Annual EAU Congress in Paris, France over t...
|
|
Myriad's Prolaris(R) Test Shown to Significantly Predict Prostate Cancer Outcome in Needle Biopsy Tissue
Feb 24, 2012
|
15.5 KB |
|
| |
SALT LAKE CITY, Feb. 24, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a study published in the British Journal of Cancer demonstrated the prognostic ability of the Company's Prolaris test in needle biopsy material. The study entitled, "Prognostic Value of a Cell Cycle Progression Signature for Prostate Cancer De...
|
|
Myriad Genetics to Present at the Cowen and Company 32nd Annual Health Care Conference
Feb 22, 2012
|
11.7 KB |
|
| |
SALT LAKE CITY, Feb. 22, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, President, Myriad Genetic Laboratories, Inc., is scheduled to present at the Cowen and Company 32nd Annual Health Care Conference, at 8:00 a.m. Eastern Time on Tuesday, March 6, 2012. The conference is being held at The Boston Mar...
|
|
Myriad Genetics to Present at the Leerink Swann 2012 Global Healthcare Conference
Feb 6, 2012
|
11.6 KB |
|
| |
SALT LAKE CITY, Feb. 6, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Jim Evans, Chief Financial Officer, is scheduled to present at the Leerink Swann 2012 Global Healthcare Conference, at 11:00 a.m. Eastern Time on Thursday, February 16, 2012. The conference is being held at the Waldorf Astoria Hotel in New York...
|
|
Myriad's Prolaris(R) Test Shown to Significantly Predict Biochemical Recurrence Risk After Prostatectomy
Feb 2, 2012
|
15.7 KB |
|
| |
SALT LAKE CITY, Feb. 2, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled, "Validation of a panel of cell-cycle progression genes for improved risk-stratification in a contemporary radical prostatectomy cohort," was presented on Thursday, February, 2, 2012 at the 2012 Genitourinary Cancers Sym...
|
|
Myriad Genetics Reports Second Quarter Fiscal Year 2012 Results
Jan 31, 2012
|
24.1 KB |
|
| |
SALT LAKE CITY, Jan. 31, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its second fiscal quarter and six months ending December 31, 2011. Revenue for the second fiscal quarter was $122.8 million, an increase of 22 percent over the $100.4 million reported in the second fiscal quarter of 2011. Earnings per d...
|
|
Myriad Genetics Acquires Exclusive Rights to RAD51C Gene
Jan 18, 2012
|
15.7 KB |
|
| |
SALT LAKE CITY, Jan. 18, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it has obtained an exclusive license to intellectual property covering the analysis of the RAD51C gene for risk of hereditary breast and ovarian cancer. In several studies, mutations in the RAD51C gene have been identified and associated with an in...
|
|
Myriad Genetics to Announce Fiscal 2012 Second Quarter Results on Tuesday, January 31, 2012
Jan 17, 2012
|
12.2 KB |
|
| |
SALT LAKE CITY, Jan. 17, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the second fiscal quarter following the close of market on Tuesday, January 31, 2012.
The Company will also host a conference call on Tuesday, January 31, 2012 at 4:30 P.M. Eastern to review the fina...
|
|
Myriad Genetics to Present at the 30th Annual J.P. Morgan Healthcare Conference
Dec 28, 2011
|
11.6 KB |
|
| |
SALT LAKE CITY, Dec. 28, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the 30th Annual J.P. Morgan Healthcare Conference, at 1:30 p.m. Pacific Time on Wednesday, January 11, 2012. The conference is being held at the Westin St. Francis Hotel in San Fr...
|
|
Myriad Genetics Presents BRACAnalysis(R) Cost-Effectiveness Study at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Dec 9, 2011
|
17.0 KB |
|
| |
SALT LAKE CITY, Dec. 9, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled "Cost Effectiveness Analysis of Genetic Testing for Breast and Ovarian Cancer Susceptibility Genes (BRCA1/BRCA2)," was presented on Thursday, December 8, 2011 during the 2011 CTRC-AACR San Antonio Breast Cancer Symposium...
|
|
Myriad Genetics to Present at the 22nd Annual Oppenheimer Healthcare Conference
Dec 1, 2011
|
14.2 KB |
|
| |
SALT LAKE CITY, Dec. 1, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, President, Myriad Genetic Laboratories, Inc., is scheduled to present at the Oppenheimer Healthcare Conference, at 9:40 a.m. Eastern Time on Wednesday, December 14, 2011. The conference is being held at the Waldorf Astoria Hotel in...
|
|
Myriad Genetics to Attend the 23rd Annual Piper Jaffray Health Care Conference
Nov 21, 2011
|
13.7 KB |
|
| |
SALT LAKE CITY, Nov. 21, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it will meet with investors at the 23rd Annual Piper Jaffray Health Care Conference on Tuesday, November 29, 2011. The conference is being held at The New York Palace Hotel in New York, New York.
About Myriad Genetics
Myriad ...
|
|
Myriad Genetics Receives the "Corporate Spirit of Giving Award" From the Utah Philanthropy Day Committee
Nov 2, 2011
|
13.9 KB |
|
| |
SALT LAKE CITY, Nov. 2, 2011 /PRNewswire/ -- Myriad Genetics, Inc. (NASDAQ: MYGN) is proud to announce its receipt of the 2011 "Corporate Spirit of Giving Award" by the Utah Philanthropy Day Committee. The award is given annually to a company that has made outstanding philanthropic and charitable service contributions to the community. The award ...
|
|
|
0.06
